Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Other Non Operating Income (2021 - 2025)

Amylyx Pharmaceuticals has reported Other Non Operating Income over the past 5 years, most recently at $362000.0 for Q4 2025.

  • Quarterly results put Other Non Operating Income at $362000.0 for Q4 2025, up 130.57% from a year ago — trailing twelve months through Dec 2025 was -$699000.0 (up 42.42% YoY), and the annual figure for FY2025 was -$700000.0, up 42.34%.
  • Other Non Operating Income for Q4 2025 was $362000.0 at Amylyx Pharmaceuticals, up from -$180000.0 in the prior quarter.
  • Over the last five years, Other Non Operating Income for AMLX hit a ceiling of $362000.0 in Q4 2025 and a floor of -$747000.0 in Q1 2024.
  • Median Other Non Operating Income over the past 5 years was -$111000.0 (2023), compared with a mean of -$158750.0.
  • Biggest five-year swings in Other Non Operating Income: soared 187.67% in 2022 and later tumbled 1278.95% in 2023.
  • Amylyx Pharmaceuticals' Other Non Operating Income stood at -$59000.0 in 2021, then plummeted by 1067.8% to -$689000.0 in 2022, then surged by 124.82% to $171000.0 in 2023, then dropped by 8.19% to $157000.0 in 2024, then soared by 130.57% to $362000.0 in 2025.
  • The last three reported values for Other Non Operating Income were $362000.0 (Q4 2025), -$180000.0 (Q3 2025), and -$546000.0 (Q2 2025) per Business Quant data.